Comprehensive Insights Provided into the Epidemiology Segments and Forecasts, the Future Growth Potential of Diagnosis Rate, Disease Progression, and Diagnostic GuidelinesDublin, Dec. 05, 2024 (GLOBE ...
AstraZeneca's IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo AstraZeneca's IMFINZI (durvalumab) has been approved in the US for the treatment of adult ...